Management of Panhypopituitarism
Panhypopituitarism requires lifelong replacement of all deficient hormones with hydrocortisone as first-line glucocorticoid therapy (15-25 mg/day in adults, 10-20 mg/day for secondary insufficiency), levothyroxine for thyroid replacement, sex steroids for hypogonadism, growth hormone when indicated, and desmopressin for diabetes insipidus, with glucocorticoid replacement always initiated before thyroid hormone to prevent adrenal crisis. 1, 2
Glucocorticoid Replacement (Priority #1)
Hydrocortisone is the recommended first-line glucocorticoid for both primary and secondary adrenal insufficiency. 1, 3
Dosing Regimen
- Adults with secondary adrenal insufficiency: 10-20 mg/day hydrocortisone (lower than primary adrenal insufficiency) 1
- Adults with primary adrenal insufficiency: 15-25 mg/day hydrocortisone 3
- Pediatric patients: 8-10 mg/m²/day for corticotroph deficiency (higher doses of 8-15 mg/m²/day for primary insufficiency) 1
- Dosing schedule: Split into 2-3 divided doses daily, with the highest dose in the morning; 3 doses recommended for infants and young children 1
Critical Safety Measures
All patients must receive comprehensive education on stress dosing and carry emergency glucocorticoid injection kits. 4
Stress Dosing Protocol
- Minor stress (fever, infection, dental work): Double the routine oral dose (typically 40 mg hydrocortisone daily in 3 divided doses) 4, 1, 5
- Moderate to major stress (severe illness, surgery, trauma): 100 mg hydrocortisone IV/IM immediately, followed by 200 mg/24h continuous IV infusion or 100 mg IV/IM every 6 hours 4, 6
- Persistent vomiting/inability to take oral medication: Administer parenteral hydrocortisone (100 mg IM or SC) 1, 4
Emergency Preparedness Requirements
- Steroid emergency card and medical alert bracelet/necklace stating "Adrenal insufficiency – needs steroids" 4
- Emergency injection kit with 100 mg hydrocortisone vials, syringes, and needles 4, 1, 4
- Patient and family education on self-administration of parenteral hydrocortisone 1, 4
- Written instructions for emergency department staff 4
Thyroid Hormone Replacement
Levothyroxine replacement for central hypothyroidism must always be initiated AFTER glucocorticoid replacement to avoid precipitating adrenal crisis. 7, 2
Key Management Points
- Start with low-dose levothyroxine and titrate based on free T4 levels (not TSH, which remains low in central hypothyroidism) 2
- TSH cannot be used for monitoring in secondary hypothyroidism; use free T4 in mid-to-upper normal range 2
- Wait at least 18-24 hours after last hydrocortisone dose before biochemical testing of HPA axis 2
Sex Steroid Replacement
Males with Central Hypogonadism
- Measure serum testosterone, FSH, and LH for diagnosis 2
- Testosterone replacement therapy when fertility is not desired 8
- When fertility is required, use gonadotropin therapy targeting secondary/tertiary hormonal levels 8
Females with Central Hypogonadism
- Estrogen replacement therapy in premenopausal women 8
- Women of childbearing age should be warned about risk of premature ovarian insufficiency in autoimmune cases 1
- Gonadotropin therapy when fertility is desired 8
Growth Hormone Replacement
Daily subcutaneous GH administration for documented GH deficiency in adults and children. 8
- Dosing and monitoring should be individualized based on IGF-1 levels and clinical response 8
- Once-weekly formulations are under development but daily administration remains standard 8
Diabetes Insipidus Management
Desmopressin is the treatment of choice for central diabetes insipidus. 6, 8
Dosing Options
- Injectable (IV/IM/SC): 1-2 µg once or twice daily 6
- Intranasal spray: 5-20 µg 2-3 times daily 6
- Sublingual lyophilisate: 60-120 µg 2-3 times daily (lower risk of hyponatremia than intranasal) 6
- Duration of action: Approximately 8 hours 6
Critical Safety Monitoring
- Risk of hyponatremia from overdosage or excessive fluid intake 6
- Educate patients on signs of water intoxication: headache, nausea, confusion, seizures 6
- Discontinue treatment if signs of water intoxication occur until polyuria returns 6
- Monitor serum sodium closely, especially when combined with glucocorticoid therapy 6
Monitoring and Follow-up
Patients should be evaluated by an endocrinologist at least annually (infants every 3-4 months) with clinical assessment for signs of over- or under-replacement. 4
Clinical Monitoring Parameters
- Glucocorticoid replacement: Assess for signs of over-dosage (weight gain, bone loss, metabolic/cardiovascular effects) or under-dosage (fatigue, hypotension, weight loss) 1
- Mineralocorticoid assessment (if applicable): Blood pressure, salt appetite, edema, serum sodium/potassium, plasma renin 1
- Thyroid replacement: Free T4 levels (not TSH in central hypothyroidism) 2
- Do NOT use routine hormonal markers (cortisol, ACTH) for glucocorticoid dose adjustment 1
Screening for Associated Conditions
In autoimmune cases, perform annual screening for associated autoimmune disorders. 4, 1, 4
- Thyroid disease: TSH, anti-thyroperoxidase antibodies 1
- Diabetes mellitus: Fasting glucose, anti-GAD antibodies, anti-IA2 antibodies 1
- Celiac disease: Anti-transglutaminase antibodies 4, 1
- Autoimmune gastritis: Blood cell count, vitamin B12, anti-gastric parietal cell antibodies, anti-intrinsic factor antibodies 1
- Premature ovarian failure in women of childbearing age 4, 1
Special Considerations
Pregnancy Management
- Requires specialized endocrine care with modifications in replacement therapy 9, 8
- Close monitoring throughout pregnancy and postpartum period 9
Genetic Counseling
- Recommended for patients with monogenic disorders causing hypopituitarism 4, 1
- First-degree relatives should be warned of signs of adrenal insufficiency and thyroid dysfunction 1
Common Pitfalls to Avoid
- Never start thyroid hormone before glucocorticoid replacement 7
- Never rely on random cortisol levels for diagnosis 2
- Never use TSH to monitor thyroid replacement in central hypothyroidism 2
- Never underestimate the need for repeated patient education on stress dosing 4
- Adrenal crisis remains a significant cause of mortality despite treatment 4